Risk/benefit decisions – who should be involved, and are there valid measurement methods?
By Clare Gurton (cgurton@rxcomms.com) Here we summarise a recent article from ISPOR Connections 2006; December 15: 3–5 Patients are generally not included in decision-making yet they are the group to…